Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the explanation...makes sense.
Do you believe the simultaneous high levels of selling along with buying means MM's are involved just like last summer, leaving many of us holding the proverbial bag?
Still, 501k application approval would lead to exterior uses only, correct? Isn't the timeline rather long for the internal surgery approval, and there have been no human trials thus far? I'm guessing the latter is where the big bucks come in and that's for the distant future.
I hope your sense of the increase is correct. Unfortunately, I've learned that plenty of people without any special information just slowly pump it up, only to dump it. The long term investors need to block out all this inexplicable movement up and down. If we believe in it, these relatively small movements don't mean a whole lot. Or am I missing something?
Thanks a million F1ash! Do you know if Norchi has ever addressed why AC5 is a superior product, by chance? I'm assuming there must be significant enough differences for them to have won the patent case in Japan. Do you mind saying if you are still 100% "in" with ARTH?
I do believe it has so much going for it, but can't block out my questions, which grew particularly with the wording of whether the 510k would be approved and the mess up with the CE application.
Is this quote correct and, if so, what is AC5 substantially equivalent to? "A 510(k) is a premarketing submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE), to a legally marketed device that is not subject to premarket approval (PMA)."
With all we've been discussing regarding the question of whether a 510k application will be approved, I'd be grateful if someone could clarify this. AC5 is unique and for that reason valuable, so I'm confused about what the company proposes the "substantially equivalent" device might be.
If I'm a millionaire at my age (the hard way, no inheritance, no penny stocks, and not counting home equity), why did I ever think I didn't know enough about investing already? Time to revert to investing what I truly feel comfortable losing...that's quite sufficient... just less than what I've held in ARTH.
Norchi is making a half million a year. So it's starting to open my eyes. He wins either way, as much as I trust his intentions.
I'm definitely out of my league here. I should have stuck with my original plan (small amount, whatever I could afford to lose), but shifted gears and pulled money from a very reliable fund that yielded 22% last year after expenses. That's not the sum total of cost though, as we learned in 08... you can recover and buy cheap, but how do you account for the lost opportunity costs of time and compounding of a seemingly low yield of 22%?
Still I'm convinced at this point that there are plenty who make mischief with these penny stocks. Even the 510k filing--when it happens--isn't nearly as significant a milestone as its approval. So why does it surge and drop like clockwork absent any tangible reason?
Thanks, good to know. I did see someone post all gung ho as if they were a long-term supporter...when I checked they were brand spanking new with two total posts noted. : )
I'm long-term ARTH, but having lived through this a few times prior, it appears that the occasional P&D traders join the fun for a few extra bucks in the interim...they move in and out. Wondering if some even change their pseudonyms to post and help with the scheme.
Funny how it only takes a few pennies up to make me happy. Helps that it's Friday!
He's not the first person to mention a r/s, and it wouldn't necessarily be a bad move. Wouldn't that help get us on the NASDAQ? I don't think everyone with challenging questions has an ulterior motive. It's becoming difficult to remain patient. ARTH has a ton of things going for it, principally the founders and MIT, but that doesn't mean that no one has any questions about when and how (not necessarily whether!) the next milestone will take place.
Still, it's hard to overlook the CE mess...that timeline is way past due and the rationale for the delay was rather concerning (mixed up paperwork/forms). Then it now turns out there's a new process for the CE mark....if I'm remembering correctly.
How low do folks think this is going to go?? It's torture.
I certainly learned a valuable lesson in greed...when the stock quintupled, there would have been no harm in selling. Isn't a 5x profit better than I'd ever done in such a short time? Then I could have repurchased if it were to drop, as it turns out, it did. I'm hard wired for long-term investing. This is the one time it worked against me. I'm still hanging on, all the while kicking myself!!!
Do you think Dhillon took advantage of more honest principals of Arch Therapeutics? Knew how to manipulate the situation to his benefit?
You raise a good point about the results never having been published. Not sure that was critical, but it's unusual that no medical publications carried the story (even in short form). If anyone know if anything was published please correct this information.
Now this is helpful! Thank you.
Many thanks Bobby D. That's very helpful.
Divea and others have influenced my thinking on Dhillon, especially with the payment for articles. I'm not in total denial on that issue. My faith, like yours, is in Norchi especially as well as some of the other principals.
Can you add some context? Divea, I don't expect you to respond to me, since you never answer my more challenging questions.
If the EU standards allow for 3-day approval for medical devices, that would be worse than third world medical standards. That just doesn't add up unless the device in question already received approval from other nations--in the developed world--that meet European standards.
If it's a 3-day standard, let Arch Therapuetics know to whom the check should be addressed or where to send the suitcase full of unmarked $100 bills. Then we'll be good to go!
What was the "huge mistake"?
Fair enough, thank you! I hope that 2013 coincides with Dhillon's arrival. If so, they could perhaps do well enough without him.
Harriet Lefton mentions ARTH, but on the SEC's site, there's no mention of ARTH, just other microcaps. Hmmmmm.... Do you have any link to the SEC sources, which I could not find? I did find the list of companies accused, just that ARTH wasn't included.
It still appears that the SEC didn't confirm whether the articles or positive posts were paid for. Do you think there might be overreach here? I would think they would only pursue cases where they know money has changed hands, otherwise--presumably--any of us posting positive notes could be liable as well. It just doesn't make a whole lot of sense to me without knowing who paid what to whom (IF at all!).
Found it, thanks.
Any reason you didn't include a link to the article? I can't find what you are referring to.
Think you nailed it, Dane! LOL
Thanks, justfactsman. I should recognize the players by now, but I'm decidedly a newbie. Patience is important. As you said, be confident in the stock...one worth holding for the long haul.
And the silence is deafening...
I guess they can only repeat themselves so many times. We just have to be patient. Still, the opportunity cost of having a pile of cash doing nothing is not for the faint-hearted
Make that 3 of us!
Hi again, divea! I thought you were expressing concern that we were getting ripped off. Which is it? Concern or glee?
I still wonder about the questions I asked you a week or two ago. I couldn't find the information you mentioned re. MKAU and who it involved (beyond your claim of Dhillon). I honestly am interested, assuming you might possibly actually be trying to help.
Paradoxically, I only fell upon this stock because of my utmost trust and personal knowledge of one of the principal's integrity (isn't Google grand?).
I'm just barely humble enough not to jinx myself with any assumptions in that regard. Please excuse my feeble attempt at humor...might not have been received as intended. The only benefit I see in retirement is not having to deal with the few unavoidable blowhards, a benefit not to underestimated, to be sure!
You might want to reconsider bragging about retirement, albeit something to which we all inexplicably aspire. There's usually only one other major life-changing event that awaits us thereafter.
Thanks so much, Lakingsphan. I'm going to do my DD. This looks promising! I'll keep you posted.
I looked up MKAU when you first mentioned it a couple posts ago, but couldn't find anything.
I'm assuming you don't have an answer for my other questions, re. the involvement of MIT and CURAM, as well as the patents (easily proven).
With your latest post, am I to presume you are actually invested in ARTH, in spite of your previous comments? Help! What gives?
I welcome you're input, but have to admit you're confusing me with the focus on MKAU and Dhillon. You mention others in general but not by name involved in MKAU and now ARTH...can you connect the dots for me?
Divea, how do you see the connection with MIT? Aren't there legal implications for making these product claims out of whole cloth, just to bilk investors? Why did they spend time and money on patents? And the study in Ireland was sponsored by a university research center; are they colluding in this? It seems implausible, but I'd be grateful for how you see that part of the picture.
Hi Divea, I looked up MKAU and see no relationship to the CEO. I actually welcome you're contrary opinions and would be grateful if you would clarify. Were you referring to the way the company was established when the markets crashed in 08 and there was minimal to no liquidity, or are you referring to something else? I know you don't like Avtar Dhillon, but he's not the CEO. Appreciate your insight.
I agree with you Codaras. The Chinese don't "play fair." It would be better to leave them until after ARTH is on solid footing with a higher share price IMHO.
CORRECTION...volume at 1000. I was using Marketwatch, and it didn't update volume simultaneously with the morning's chart price. Sorry!!
Volume this morning is already almost 800K, with the price holding at 69ish. I suppose that's a good sign??